 t 2024 . 
Key developments 2024 
The CEO summarizes the company’s overall performance in the CEO comments in the Annual report 
2024 . 
The company’s remuneration guidelines: scope, purpose and deviations 
A prerequisite for the successful implementation of the company’s business strategy and 
safeguarding of its long -term interests, including its sustainability, is that the company can recruit 
and retain qualified personnel. To this end, the company must off er competitive remuneration. The 
company’s remuneration guidelines enable the company to offer executives a competitive total 
remuneration. Under the remuneration guidelines, executive remuneration shall be on market terms 
and may consist of the following components: fixed salary, variable remuneration, long -term 
incentive programs, pension s and other customary benefits. The variable cash remuneration shall be 
linked to financial or non -financial criteria. They may be individualized, quantitative or qualitative 
objectiv d share price -related incentive plans 
The company currently has seven outstanding combined share award and employee stock option 
programs (LTIP Stay -on 2021/2024 , LTIP 2022/2025 , LTIP Stay -On 2022/2025 , LTIP 2023/202 6, LTIP 
Stay -On 2023/2026 , LTIP 2024/2027 and LTIP Stay -On 2024/2027 ) for senior executives and

employees within the group , and for certain Global Management Team and US Leadership Team 
employees, respectively . 
LTIP 2021/2024 (vested during 2024) 
The number of share awards and employee stock options that entitle to shares depends on the 
outcome of the performance conditions set by the Board . The performance conditions focus on the 
holder still being employed by the Orexo group (“Performance Target 1”) and on Orexo’s financial 
and operational targets for 202 1 (“Performance Target 2” and together the “Performance Targets”). 
Of each participant’s granted share awards, approximately 33% (one third) will pertain to 
Performance Target 1 and up to approx Performance Targets. Vesting period means the three -year period from the award date. The part of 
the program relating to Opt -in 1 may not start later than 31 August 202 1 and consequently end no 
later than on 31 August 202 4. The part of the program relating to Opt -in 2 may not start later than 
31 May 2022 and consequently end no later than on 3 1 May 2025 . The CEO has been granted 3 000 
share awards and 3 000 employee stock options. In total, 10,473 share awards and 10,473 employee 
stock options have been granted, which corresponds to 0 .06% of the shares in the company on a 
diluted basis. 
LTIP 2022/2025 
The number of share awards and employee stock options that entitle to shares depends on the 
outcome of the performance conditions set by the Board . The performance conditions focus on the 
holder still being employed by the Orexo group (“Performance Target 1”) and on Orexo’s financial 
and operational targets for 202 2 (“Performance Target 2” and together the “Performanc ther the “Performance Targets”). 
Of each participant’s granted share awards, approximately 33% (one third) will pertain to 
Performance Target 1 and up to approxim ately 67% (two thirds) will pertain to Performance Target 
2. Of each Participant’s granted employee stock options, 100% will pertain to Performance Target 1, 
meaning that no Employee stock options will vest unless the performance target is met. The

allotment of shares that each participant later may receive depends on achievement of the 
Performance Targets. Vesting period means the three -year period from the award date. The program 
started on 1 2 May 2022. The CEO has been granted 57,900 share awards and 135,300 employee 
stock options. In total, 515,850 share awards and 1,202,750 employee stock options have been 
granted, which corresponds to 4.95 % of the shares in the company on a diluted basis. 
LTIP Stay -on 2022/2025 
Qualification for participation in the program is conditional upon the participant (i) keeping  0% will pertain to Performance Target 1 and 50% will pertain to Performance Target 
2. Of each Participant’s granted employee stock options, 100% will pertain to Performance Target 1, 
meaning that no employee stock options will vest unless the performance target is met. The 
allotment of shares that each participant later may receive depends on achievement of the 
Performance Targets. Vesting period m eans the three -year period from the award date. The part of 
the program relating to Opt -in 1 may not start later than 31 August 2023 and consequently end no 
later than on 31 August 2026. The part of the program relating to Opt -in 2 may not start later than 
31 May 2024 and consequently end no later than on 31 May 2027. The CEO has been granted 2,627 
share awards and 2,627 employee stock options. In total, 6,622 share awards and 6,622 employee

stock options have been granted, which corresponds to 0.0 4% of the shares in the company on a 
diluted basis. 
Table 1 – Total CEO remunera  its entirety relates to Base salary and is premium defined, has been counted 
entirely as fixed remuneration. 
 
Table 2 – Change of remuneration and company p erformance over the last four reported financial 
years (RFY) (kSEK) 
 
 RFY 2024 RFY 2023 RFY 2022 RFY 2021 RFY 2020 
CEO remuneration 6,565 5,984 5,972 9,887 10,678 
Group operating profit -140,325 -109,515 -183,895 -214,084 -19,900 
Average remuneration on a full time equivalent 
basis of employees* of the parent company 767 705 660 698 681 
 
* Excluding members of the executive management.

Application of performance criteria 
 
The performance measures for the CEO’s variable remuneration have been selected to deliver the company’s strategy and 
to encourage behaviour which is in the long -term interest of the company. In the selection of performance measures, the 
strategic objectives and short -term and long -term b usiness priorities defined and measured in the Balanced Scorecard for 
2023 have been taken into account.  taken into account. The non -financial performance measures further contribute to alignment with 
sustainability as well as the company values. 
Table 3 (a) – Performance of the CEO in the reported financial year: variable cash remuneration * 
Name of 
director 
(position) 1 
Description of the criteria related to the 
remuneration component 2 
Relative weighting of 
the performance 
criteria 3 
a) Measured performance and 
b) actual award/ remuneration outcome 
Nikolaj 
Sørensen 
(CEO) Finance Goals 40 % a) 105 % 
Business Processes – Initiatives with 
defined targets 30 % a) 92 % 
Customers & Society – Defined targets 
regarding Zubsolv and D MHP (earlier DTx) 20 % a) 76 % 
People & Organization – Number and 
severity of compliance issues and staff 
engagement score in Annual employee 
survey 
 10 % a) 117 % 
 Total outcome after board adjustment a) 96.3 % 
b) 90 % 
c) 1,326 kSEK 
 
* Based on the company’s Balanced Scorecard for 2023. 
 
Table 3 (b) – Performance of t he CEO in the   of t he CEO in the reported financial year: share -based incentives 
 
 
* In addition to the performance criteria described, continued employment is required for vesting. 
** Stock options are not included in the table. 
*** The performance period is still running. Name of 
director 
(position) 
Name of plan 1 
Description of the criteria related to the 
remuneration component 2 
Relative weighting of the 
performance criteria* 3 
a) Measured performance and 
b) actual award/remuneration 
outcome 
Nikolaj 
Sørensen 
(CEO) LTIP 2024/2027** 
 Fulfilment of the financial and operational 
targets for the financial year 2024 as established by 
the 
Board of directors and relates to 
the company’s key KPIs as per Balanced Scorecard 67 % a) 94 % 
b) N/A*** 
 
LTIP Stay on 
2024/2027 Opt in 
1+2** Fulfilment of the financial and operational 
targets for the financial year 2024 as established by 
the 
Board of directors and relates to 
the company’s key KPIs as per Balanced Scorecard 50 % 
 
